Virax Biolabs Advances Post-Acute Infection Syndrome Diagnostics with Completed UK Trial Recruitment and FDA Engagement
Key Insights
Virax Biolabs (search) completed recruitment for its first UK clinical study (VRX-002) ahead of schedule, enrolling 160 participants across Long COVID (search), post-treatment Lyme disease (search), and ME/CFS cohorts with initial data expected in Q2 2026.
The company established a clinical collaboration with Emory University's ADJUST Center to support U.S. regulatory plans for its ViraxImmune (search)™ T cell assay in post-acute sequelae of COVID-19.
Mechanistic data presented at WIRM showed progressive up-regulation of T cell exhaustion markers in PAIS patients, supporting the rationale for ViraxImmune (search)™ diagnostic technology.
Virax Biolabs (search) Group Limited has achieved significant clinical milestones in developing diagnostic technology for post-acute infection syndromes (search) (PAIS), completing recruitment for its pivotal UK study ahead of schedule and establishing key regulatory pathways in both the UK and United States.
The biotechnology company announced completion of patient recruitment for its first UK multicentre clinical study (VRX-002) in November, reaching the full target of 160 participants across Long COVID (search), post-treatment Lyme disease (search) (PTLD), and myalgic encephalomyelitis/chronic fatigue syndrome (search) (ME/CFS) cohorts. The collected samples are now undergoing detailed immunological analysis, with initial data readouts expected in the second quarter of 2026.
Clinical Progress Across Multiple Studies
The company has initiated two UK-based clinical studies evaluating its ViraxImmune (search)™ T cell assay. The first study (VRX-002) involves 160 subjects across five clinical centres in collaboration with the National Health Service (NHS), designed to generate clinical data required to support planned regulatory submissions to the UK Medicines and Healthcare products Regulatory Agency (MHRA).
A second UK-based clinical study (VRX-003) involving 100 subjects and conducted by Eurofins (search) was initiated in April and is now fully enrolled. These studies are intended to establish the clinical utility of ViraxImmune (search)™ in characterizing immune dysfunction associated with PAIS.
Scientific Evidence Supporting T Cell Dysfunction
At the 19th World Immune Regulation Meeting (WIRM) in Davos, Switzerland, Virax presented mechanistic data demonstrating T cell exhaustion and dysfunction in PAIS patients. The data showed progressive up-regulation of multiple exhaustion markers including PD-1 (search), LAG-3 (search), TIGIT (search), TIM-3 (search), and CD39 (search) with repeated antigen stimulation, alongside changes in cytokine profiles in PAIS patients versus healthy controls.
According to CEO James Foster, "the findings suggest that many PAIS patients show clear signs of ongoing T cell dysfunction, which is consistent with the type of immune dysfunction that ViraxImmune (search)™ is designed to characterise."
U.S. Regulatory and Clinical Development
Virax has established a Research Services Agreement with Emory University's ADJUST Center and the Emory Laboratory for Innovative Assay Development (ELIAD). Under this collaboration, Emory will conduct clinical studies of ViraxImmune (search)™ focusing initially on post-acute sequelae of COVID-19 (PASC), generating data to inform U.S. regulatory strategy and potential commercial plans.
The company held an in-person pre-submission meeting with the FDA to discuss the proposed intended use and regulatory pathway for ViraxImmune (search)™ in PASC. The final meeting minutes, received in autumn 2025, provided constructive feedback on clinical and analytical development plans, which the company is incorporating into its planned U.S. clinical study design with Emory University, anticipated to initiate in 2026.
Commercial Portfolio Development
Alongside its diagnostic development, Virax continues advancing its ImmuneSelect (search) research-use-only (RUO) portfolio of peptide pools, ELISpot plates and related reagents. These products can be commercialized without waiting for diagnostic approvals and offer potential near-term revenue generation as adoption builds among research and biopharmaceutical customers working on chronic infection, inflammation and immune dysfunction.
Financial Position and Strategic Outlook
As of September 30, 2025, Virax maintained approximately $3.3 million in cash and cash equivalents with total assets of $5.7 million, total liabilities of $0.6 million, and no long-term debt. The company's market capitalization of approximately $1.7 million represents trading below its cash balance at a negative implied enterprise value.
Foster noted that "the progress in 2025 has significantly reduced the clinical execution risk for ViraxImmune (search)™ and positioned us for an important data year ahead." The company's 2026 priorities include delivering initial data from the UK PAIS study, initiating U.S. clinical work with Emory University, and expanding commercial uptake of ImmuneSelect (search) RUO products.
The company is evaluating potential U.S. laboratory-based testing service offerings for ViraxImmune (search)™ through appropriate laboratories, subject to applicable regulatory requirements, as a way to begin building early clinical experience and market familiarity with the assay.